TLR4 and inflammatory bowel disease: Altogether, this study demonstrated that PSG could not only inhibit IBD via inhibiting the LPS/TLR4/MyD88/NF-κB pathway but also protect secondary liver injury via suppressing pyroptosis and oxidative injury (Figure 10).